List of Trials

Horizon Oncology and Research Center offers cutting edge clinical trial opportunities. Principal investigators and research nurses from our research center have access to numerous clinical trials that are investigating breakthrough cancer therapies.

Hematologic Malignancies

Vanda-VTR-297-1101-A Phase I multicenter, open label, dose-escalation study to determine the maximum tolerated does for Trichostatin A in subjects with replapsed or refractory Hematologic Malignancies.

Gastrointestinal and Genitourinary Tumors

  • Pharmacyclics-PCYC-1128 CA- A Phase 1b/2 Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal And Genitourinary Tumors

Epithelial Tumors

  • PSI Oxus- ColoAD 1003-Phase 1 multicentre, open label study of enadenotucirev combined with PD-1 inhibitor in subjects with metastatic or advanced epithelial tumors.


  • Constellation-0610-02- A Phase 1/2 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins: Phase 1 (Dose Escalation of CPI-0610 in Patients with Hematological Malignancies) and Phase 2 (Dose Expansion of CPI-0610 with and without Ruxolitinib in Patients with Myelofibrosis)

Solid Tumors

  • Pfizer-B9991033-A Phase 1B/2 study to evaluate safety and clinical activity of Avelumab in combination with Binimetinib with or without Talazoparib in patients with locally advanced or metastatic RAS-mutant solid tumors.
  • AstraZeneca- D5660C00004 (AZD9150 ) is A Phase 1b/2, Open -Label, Multicentre Study Assessing the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of MEDI4736 in Combination With AZD9150 or AZD5069 in Patients With Advanced Solid Malignancies and Subsequently Comparing AZD9150 and AZD5069 Both as Monotherapy and in Combination With MEDI4736 as Second Line Treatment in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck.
  • AstraZeneca D5660C00016- A Phase Ib/II, Open – Label, Multicentre Study to Assess Safety, Tolerability , Pharmacokinetics and Preliminary Anti-tumour Activity of AZD9150 plus Durvalumab alone or in Combination with Chemotherapy in Patients with Advanced, Solid Tumours and Subsequently in Patients with Non-Small-Cell Lung Cancer.
  • Vigeo- VT1021-01A Phase 1 Study Evaluating the Safety, Pharmacology, and Preliminary Activity of VT1021 in Patients with Advanced Solid Tumors
  • Boston Biomedical- BBI – DSP7888 – 102CI- A Phase 1b /2 , Multicenter, Open -Label Study of DSP -7888 Dosing Emulsion in Combination with Immune Checkpoint Inhibitors Nivolumab or Pembrolizumab in Adult Patients with Advanced Solid Tumors


  • LAM Therapeutics-LAM-002A-NHL-CLN01-A Phase 1 dose escalation study of the safety and pharmacokinetics of LAM-002A (Apilimod Dimesylate Capsules) administered orally in subjects with relapsed or refractory B-Cell Non-Hodgkin’s Lymphoma

Lung Cancer

  • Heat-HA110-102- A Phase 1B/2 Study of Viagenpumatucel-L (HS-110) in Combination with Multiple Treatment Regimens in Patients with Non-Small Cell Lung Cancer (The “Durga” Trial)

Non-Small Cell lung cancer and triple negative breast cancer

  • Pfizer C3621001- A Phase 1 Study to evaluate the safety, pharmacokinetics, and pharmacodynamics of escalating doses and treatment intensification of a vaccine-based immunotherapy regimen-2 (VBIR-2) (PF-06936308) for advanced Non-Small Cell lung cancer and metastatic triple-negative breast cancer.

Solid Tumors

  • Leap- TRX518004-A Dose Escalation and Expansion Study of TRX518 in Combination with Cyclophosphamide Plus Avelumab in Advanced Solid Tumors